CA2251414A1 - Stabilization of ascorbic acid, ascorbic acid derivatives and/or extracts containing ascorbic acid for topical use - Google Patents
Stabilization of ascorbic acid, ascorbic acid derivatives and/or extracts containing ascorbic acid for topical use Download PDFInfo
- Publication number
- CA2251414A1 CA2251414A1 CA002251414A CA2251414A CA2251414A1 CA 2251414 A1 CA2251414 A1 CA 2251414A1 CA 002251414 A CA002251414 A CA 002251414A CA 2251414 A CA2251414 A CA 2251414A CA 2251414 A1 CA2251414 A1 CA 2251414A1
- Authority
- CA
- Canada
- Prior art keywords
- composition
- ascorbic acid
- percent
- substantially anhydrous
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/004—Aftersun preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/676—Ascorbic acid, i.e. vitamin C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/20—Chemical, physico-chemical or functional or structural properties of the composition as a whole
- A61K2800/30—Characterized by the absence of a particular group of ingredients
- A61K2800/31—Anhydrous
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/52—Stabilizers
Abstract
A stable composition is provided to treat and/or prevent photo-aged skin and related skin disorders such as sunburn, wrinkles, poor skin tone and skin discoloration by topically applying to the skin the treatment composition containing an effective amount of a compound such as ascorbic acid, derivatives of ascorbic acid and/or extracts containing ascorbic acid, in a pharmaceutically acceptable vehicle containing a substantially anhydrous base having no water added. The anhydrous base stabilizes the compound, so that the compound remains effective for an effective period of time, even in the presence of exposure to water.
Preferably, the anhydrous base is a single phase carrier, as opposed to a two phase carrier emulsion.
Preferably, the anhydrous base is a single phase carrier, as opposed to a two phase carrier emulsion.
Description
STABILIZATION OF ASCORBIC ACID, ASCORBIC ACID
DERIVATIVES AND/OR EXTRACTS CONTAINING ASCORBIC ACID
FOR TOPICAL USE
FIELD OF THE INVENTION
The present invention is directed to a composition for stabilizing ascorbic acid, ascorbic acid derivatives and/or extracts containing ascorbic acid, in a stable delivery system for topical application to the skin. The composition prevents premature aging of the skin of humans, or may be used to treat photo-aged skin and resultant wrinkles and other sequelae. Preferably, the composition is an anhydrous base which is a single phase carrier, such as a dispersion or suspension, as opposed to a two phase emulsion.
BACKGROUND OF THE INVENTION
Vitamin C is a powerful antioxidant that may help neutralize the damaging effects of free radicals, the unstable chemicals that are a result of air pollution, smoking ,stress and sunlight.
Studies suggest that Vitamin C has the potential to stimulate the growth of collagen that is important in maintaining healthy skin elasticity and texture.
Vitamin C in the form of L-Ascorbic acid is the chemical form of ascorbic acid that is reported to be most effectively utilized by the body.
Treatment of photo-aged skin and resultant wrinkles and other sequelae with ascorbic acid and related derivatives has been discussed in the prior art. Among the most common treatment regimen is a topical application of ascorbic acid to affected areas of the skin in lotions, creams and other delivery vehicles, such as discussed in U.S. patent no.
5,140,043 of Darr et al for stable ascorbic acid compositions.
In Darr '043, it is noted that L-ascorbic acid prevents ultraviolet (UV) damage to the skin. In the discussion of the background art therein, Darr '043 states that ascorbic acid, also commonly known as Vitamin C, acts as an anti-oxidant to counteract the skin damaging effects of superoxide and hydroxyl radicals, which have been known to cause a wide variety of damaged skin conditions ranging from transitory sunburn to permanent wrinkles from photo-aged skin. According to Darr '043, these radicals destroy lipid membranes, break down DNA and inactivate beneficial enzymes which promote healthy skin conditions, citing Cerutti, D. et al, eds. Oxy-radicals in Molecular Biology and Pathology, (Alan Liss, publisher, New York, NY 1988), Hayaishi, O, et al, eds., Biological Role of Reactive Oxygen Species in Skin, (Elsevier Press, New York, NY 1987), Johnson, Jr., J.E. et al, eds., Free Radicals, Aging and Degenerative Diseases, (Alan Liss publisher, New York, NY 1986), Halliwell, B. et al, eds, Free Radicals in Biology and Medicine, (Clarendon Press, Oxford, U.K. 1985), and Sied, H., ed., Oxidative Stress, (Academic Press, 1985), among other cited publications therein.
2o Free radicals from ultraviolet light (UV) are known to increase with air pollution in areas of concentrated populations, thereby magnifying the problem. The free radicals are destructive in that the free radicals hydrolyse elastin fibers in the skin and desynthesize collagen in the lower dermal layers of the skin, thereby causing skin wrinkles and other damaging skin conditions.
In contrast, it has also been known that ascorbic acid is effective in counteracting the effects of free radicals upon the skin. Ascorbic acid absorbs ultraviolet (UV) radiation and at the same time stimulates collagen production.
However, ascorbic acid, such as Vitamin C, is difficult to stabilize for any significant period of time in pharmaceutical vehicles for topical delivery to the skin.
Ascorbic acid loses potency and discolors easily in most f delivery vehicles. Furthermore, ascorbic acid hydrolyzes when exposed to water.
The term "stable" is defined as a characteristic wherein a composition retains potency for the duration of a predetermined expiration period, as defined by generally accepted pharmaceutical protocols, such as "GMP", or "good manufacturing practices" as promulgated by various trade conventions, such as for example, the United States Pharmacoepia (USP) convention.
For example, for a topically applied skin care formulation, the expected duration of a predetermined expiration period should be at least eight months before the formulation loses significant potency.
In contrast, Darr '043 only tested the product described therein for twelve weeks.
Moreover, as noted in Darr '043, ascorbic acid washes off easily when exposed to water, so that topical application at a sun-lit beach is generally futile, since swimming washes away the topically applied ascorbic acid.
Furthermore, in the past, ascorbic acid has been administered in high dosages to the skin, and has to be made every day because of its instability, thus increasing cost of its use.
Darr '043 discloses a method,of stabilizing ascorbic acid in a water based delivery system with an ascorbic acid to water/carrier ratio of at least 1:1, preferably 2:1 to 10:1.
The ascorbic acid and water mix described in Darr '043 includes both water and a carrier, such as alkylene glycols, or alkylene glycols in combination with one or more derivatives of hydroxyalkyl-cellulose. However, the minimum amount of water in the product disclosed in Darr '043 is fifty (50) percent, since Darr' 043 teaches at least a 1:1 ratio of water to carrier, preferably greater than fifty (50) percent, such as sixty seven (67) percent water in a 2:1 ratio, up to ninety two (91) percent water in a 10:1 water/carrier ratio.
In general, the carrier is described as being compatible with water, preferably distilled or deionized water without contaminants, which further de-stabilize ascorbic acid.
However, the disadvantage of the delivery vehicle in Darr '043 is that it is water-based, and therefore the ascorbic acid is still inherently unstable.
l0 For example, while Figure 1 of Darr '043 shows small drops in potency of L-ascorbic acid of less than 10 percent over seven weeks at room temperature for L-ascorbic concentrations of three (3), five (5) and ten (10) percent respectively, Figure 1 shows a drop in potency of approximately 30 percent over seven weeks, from 100 percent to 70 percent, of L-ascorbic acid in a concentration of one (1) percent.
Moreover, Figure 2 of Darr '043 shows all four samples of L-ascorbic acid having lost potency of at least ten (10) percent over eight (8) weeks at room temperature, when stored under controlled conditions in the dark.
Furthermore, while the testing in Darr '043 was conducted from between seven (7) and twelve (12) weeks duration, any viable over the counter consumer product requires in excess of twelve weeks from manufacture through distribution points to final retail sale, and must still afford the consumer a reasonable time to consume the contents of the product. Therefore, a loss in potency of the magintude as shown in Darr '043 in such a short time span, raises serious questions as to the usefulness of the stability data obtained in predicted the potency of L-ascorbic acid at the time the consumer is able to use the product.
Therefore, the response of the ascorbic acid in the epidermis and dermis of the skin is not very effective, l because of the presence of substantial amounts of water, which contribute to destabilization of the ascorbic acid.
The present invention utilizes a single phase carrier, as opposed to an emulsion, as the anhydrous base. Emulsions are more complicated compositions than single phase carriers, and are discussed in Remington, Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, PA
1975, pp 327-331, Sagarin, Cosmetics Science and Technology.
Interscience Publishers, Inc., N.Y., N.Y. 1957, pp. 998-1003, Wilkinson et al, Harry's Cosmetology, Chemical Publishing Co., N.Y., N.Y. pp 729-741.
Such an emulsion for ascorbic acid is shown in U.S.
patent no. 5,587, 149 of Punto et al for a topical emulsion for ascorbic acid. Punto '149 describes two phase emulsions for stabilizing water-soluble active ingredients, such as ascorbic acid. For example, Punto '149 describes a two phase polyethylene glycol-in-oil emulsion. In Punto '149, the glycols are first dissolved in a water phase in a first phase. Secondly, an oil, such as silicone #1, is introduced in a second oil phase. Dispersion agents are then added to create an emulsion between the components of the first water phase and the second oil phase. However, Punto '149 does not describe the making of an anyhydrous base in a single phase carrier, as opposed to a two phase emulsion.
OBJECTS OF THE INVENTION
It is therefore an object of the present invention to provide a stable single phase composition and pharmaceutical delivery system for ascorbic acid, ascorbic acid derivatives and/or extracts containing ascorbic acid as effective treatments for photo-aged skin and related skin disorders.
It is yet another object to provide a topical preparation of ascorbic acid, ascorbic acid derivatives and/or extracts containing ascorbic acid for more effective treatment of photo-aged skin and related skin disorders.
It is yet a further object to provide a topical delivery vehicle for ascorbic acid, derivatives of ascorbic acid and/or extracts containing ascorbic acid, wherein the delivery vehicle is substantially anhydrous with no water added.
It is yet a further object to provide ascorbic acid, ascorbic acid derivatives and/or extracts containing ascorbic acid, in a composition wherein the ascorbic acid, ascorbic acid derivatives and/or extracts containing ascorbic acid remain effective for an extended period of time.
It is yet another object to improve over the disadvantages of the prior art.
BRIEF SUMMARY OF THE INVENTION
In keeping with these objects and others which may become apparent, according to the present invention, a new stable, long-lasting composition is provided as a pharmaceutical delivery vehicle for delivery of ascorbic acid, ascorbic acid derivatives and/or extracts containing ascorbic acid, to prevent and treat sun-damaged and photo-aged skin, and as a preventative and cosmetic for undamaged skin.
Research suggests that ascorbic acid concentrations of 10-15% are preferable to provide enhanced skin care results.
For example, the formulation of the present invention at 10% maintained 96% of the claimed L-Ascorbic Acid concentration as compared to 34% for other L-Ascorbic Acid products at 10% after 90 days.
The formulation of the present invention at 15%
maintained 100% of the claimed L-Ascorbic Acid concentration as compared to 20% for other products of L-Ascorbic Acid at 15% after 90 days.
DERIVATIVES AND/OR EXTRACTS CONTAINING ASCORBIC ACID
FOR TOPICAL USE
FIELD OF THE INVENTION
The present invention is directed to a composition for stabilizing ascorbic acid, ascorbic acid derivatives and/or extracts containing ascorbic acid, in a stable delivery system for topical application to the skin. The composition prevents premature aging of the skin of humans, or may be used to treat photo-aged skin and resultant wrinkles and other sequelae. Preferably, the composition is an anhydrous base which is a single phase carrier, such as a dispersion or suspension, as opposed to a two phase emulsion.
BACKGROUND OF THE INVENTION
Vitamin C is a powerful antioxidant that may help neutralize the damaging effects of free radicals, the unstable chemicals that are a result of air pollution, smoking ,stress and sunlight.
Studies suggest that Vitamin C has the potential to stimulate the growth of collagen that is important in maintaining healthy skin elasticity and texture.
Vitamin C in the form of L-Ascorbic acid is the chemical form of ascorbic acid that is reported to be most effectively utilized by the body.
Treatment of photo-aged skin and resultant wrinkles and other sequelae with ascorbic acid and related derivatives has been discussed in the prior art. Among the most common treatment regimen is a topical application of ascorbic acid to affected areas of the skin in lotions, creams and other delivery vehicles, such as discussed in U.S. patent no.
5,140,043 of Darr et al for stable ascorbic acid compositions.
In Darr '043, it is noted that L-ascorbic acid prevents ultraviolet (UV) damage to the skin. In the discussion of the background art therein, Darr '043 states that ascorbic acid, also commonly known as Vitamin C, acts as an anti-oxidant to counteract the skin damaging effects of superoxide and hydroxyl radicals, which have been known to cause a wide variety of damaged skin conditions ranging from transitory sunburn to permanent wrinkles from photo-aged skin. According to Darr '043, these radicals destroy lipid membranes, break down DNA and inactivate beneficial enzymes which promote healthy skin conditions, citing Cerutti, D. et al, eds. Oxy-radicals in Molecular Biology and Pathology, (Alan Liss, publisher, New York, NY 1988), Hayaishi, O, et al, eds., Biological Role of Reactive Oxygen Species in Skin, (Elsevier Press, New York, NY 1987), Johnson, Jr., J.E. et al, eds., Free Radicals, Aging and Degenerative Diseases, (Alan Liss publisher, New York, NY 1986), Halliwell, B. et al, eds, Free Radicals in Biology and Medicine, (Clarendon Press, Oxford, U.K. 1985), and Sied, H., ed., Oxidative Stress, (Academic Press, 1985), among other cited publications therein.
2o Free radicals from ultraviolet light (UV) are known to increase with air pollution in areas of concentrated populations, thereby magnifying the problem. The free radicals are destructive in that the free radicals hydrolyse elastin fibers in the skin and desynthesize collagen in the lower dermal layers of the skin, thereby causing skin wrinkles and other damaging skin conditions.
In contrast, it has also been known that ascorbic acid is effective in counteracting the effects of free radicals upon the skin. Ascorbic acid absorbs ultraviolet (UV) radiation and at the same time stimulates collagen production.
However, ascorbic acid, such as Vitamin C, is difficult to stabilize for any significant period of time in pharmaceutical vehicles for topical delivery to the skin.
Ascorbic acid loses potency and discolors easily in most f delivery vehicles. Furthermore, ascorbic acid hydrolyzes when exposed to water.
The term "stable" is defined as a characteristic wherein a composition retains potency for the duration of a predetermined expiration period, as defined by generally accepted pharmaceutical protocols, such as "GMP", or "good manufacturing practices" as promulgated by various trade conventions, such as for example, the United States Pharmacoepia (USP) convention.
For example, for a topically applied skin care formulation, the expected duration of a predetermined expiration period should be at least eight months before the formulation loses significant potency.
In contrast, Darr '043 only tested the product described therein for twelve weeks.
Moreover, as noted in Darr '043, ascorbic acid washes off easily when exposed to water, so that topical application at a sun-lit beach is generally futile, since swimming washes away the topically applied ascorbic acid.
Furthermore, in the past, ascorbic acid has been administered in high dosages to the skin, and has to be made every day because of its instability, thus increasing cost of its use.
Darr '043 discloses a method,of stabilizing ascorbic acid in a water based delivery system with an ascorbic acid to water/carrier ratio of at least 1:1, preferably 2:1 to 10:1.
The ascorbic acid and water mix described in Darr '043 includes both water and a carrier, such as alkylene glycols, or alkylene glycols in combination with one or more derivatives of hydroxyalkyl-cellulose. However, the minimum amount of water in the product disclosed in Darr '043 is fifty (50) percent, since Darr' 043 teaches at least a 1:1 ratio of water to carrier, preferably greater than fifty (50) percent, such as sixty seven (67) percent water in a 2:1 ratio, up to ninety two (91) percent water in a 10:1 water/carrier ratio.
In general, the carrier is described as being compatible with water, preferably distilled or deionized water without contaminants, which further de-stabilize ascorbic acid.
However, the disadvantage of the delivery vehicle in Darr '043 is that it is water-based, and therefore the ascorbic acid is still inherently unstable.
l0 For example, while Figure 1 of Darr '043 shows small drops in potency of L-ascorbic acid of less than 10 percent over seven weeks at room temperature for L-ascorbic concentrations of three (3), five (5) and ten (10) percent respectively, Figure 1 shows a drop in potency of approximately 30 percent over seven weeks, from 100 percent to 70 percent, of L-ascorbic acid in a concentration of one (1) percent.
Moreover, Figure 2 of Darr '043 shows all four samples of L-ascorbic acid having lost potency of at least ten (10) percent over eight (8) weeks at room temperature, when stored under controlled conditions in the dark.
Furthermore, while the testing in Darr '043 was conducted from between seven (7) and twelve (12) weeks duration, any viable over the counter consumer product requires in excess of twelve weeks from manufacture through distribution points to final retail sale, and must still afford the consumer a reasonable time to consume the contents of the product. Therefore, a loss in potency of the magintude as shown in Darr '043 in such a short time span, raises serious questions as to the usefulness of the stability data obtained in predicted the potency of L-ascorbic acid at the time the consumer is able to use the product.
Therefore, the response of the ascorbic acid in the epidermis and dermis of the skin is not very effective, l because of the presence of substantial amounts of water, which contribute to destabilization of the ascorbic acid.
The present invention utilizes a single phase carrier, as opposed to an emulsion, as the anhydrous base. Emulsions are more complicated compositions than single phase carriers, and are discussed in Remington, Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, PA
1975, pp 327-331, Sagarin, Cosmetics Science and Technology.
Interscience Publishers, Inc., N.Y., N.Y. 1957, pp. 998-1003, Wilkinson et al, Harry's Cosmetology, Chemical Publishing Co., N.Y., N.Y. pp 729-741.
Such an emulsion for ascorbic acid is shown in U.S.
patent no. 5,587, 149 of Punto et al for a topical emulsion for ascorbic acid. Punto '149 describes two phase emulsions for stabilizing water-soluble active ingredients, such as ascorbic acid. For example, Punto '149 describes a two phase polyethylene glycol-in-oil emulsion. In Punto '149, the glycols are first dissolved in a water phase in a first phase. Secondly, an oil, such as silicone #1, is introduced in a second oil phase. Dispersion agents are then added to create an emulsion between the components of the first water phase and the second oil phase. However, Punto '149 does not describe the making of an anyhydrous base in a single phase carrier, as opposed to a two phase emulsion.
OBJECTS OF THE INVENTION
It is therefore an object of the present invention to provide a stable single phase composition and pharmaceutical delivery system for ascorbic acid, ascorbic acid derivatives and/or extracts containing ascorbic acid as effective treatments for photo-aged skin and related skin disorders.
It is yet another object to provide a topical preparation of ascorbic acid, ascorbic acid derivatives and/or extracts containing ascorbic acid for more effective treatment of photo-aged skin and related skin disorders.
It is yet a further object to provide a topical delivery vehicle for ascorbic acid, derivatives of ascorbic acid and/or extracts containing ascorbic acid, wherein the delivery vehicle is substantially anhydrous with no water added.
It is yet a further object to provide ascorbic acid, ascorbic acid derivatives and/or extracts containing ascorbic acid, in a composition wherein the ascorbic acid, ascorbic acid derivatives and/or extracts containing ascorbic acid remain effective for an extended period of time.
It is yet another object to improve over the disadvantages of the prior art.
BRIEF SUMMARY OF THE INVENTION
In keeping with these objects and others which may become apparent, according to the present invention, a new stable, long-lasting composition is provided as a pharmaceutical delivery vehicle for delivery of ascorbic acid, ascorbic acid derivatives and/or extracts containing ascorbic acid, to prevent and treat sun-damaged and photo-aged skin, and as a preventative and cosmetic for undamaged skin.
Research suggests that ascorbic acid concentrations of 10-15% are preferable to provide enhanced skin care results.
For example, the formulation of the present invention at 10% maintained 96% of the claimed L-Ascorbic Acid concentration as compared to 34% for other L-Ascorbic Acid products at 10% after 90 days.
The formulation of the present invention at 15%
maintained 100% of the claimed L-Ascorbic Acid concentration as compared to 20% for other products of L-Ascorbic Acid at 15% after 90 days.
A method of preventing and/or treating photo-aged skin, sunburn, wrinkles and related skin disorders is provided by topical application of a lotion, cream, gel or pad applied formulation, preferably a substantially anhydrous composition, with no water added, containing effective amounts of ascorbic acid, ascorbic acid derivatives and/or extracts containing ascorbic acid, for topical application to the affected area of the skin. The composition of the present invention can also be used to prevent photo-aging of the skin.
Ascorbic acid, or its derivatives, such as ascorbic palmitate, sodium ascorbate, potassium ascorbate, ammonium ascorbate, triethanolamine ascorbate, ascorbyl phosphate or magnesium ascorbyl phosphate and related compounds, is applied in a pharmaceutically acceptable vehicle, in a concentration of from 0.1 percent by weight to 95 percent by weight, preferably 10-15 percent by weight, generally by frequent periodic application, such as by a once or twice daily application.
Instead of a substantially water based delivery system, the ascorbic acid, ascorbic acid derivatives and/or extracts containing ascorbic acid are provided in a substantially anhydrous base, with no added water. Because one or more of the components may have a natural water sub-component, the base is not water free, but is substantially anhydrous, because the pre-existing water concentration does not generally exceed five (5) percent by weight of the total composition. To achieve the substantially anhydrous composition, no water is added, in contrast to the water-based composition in Darr '043.
The substantially anhydrous base protects the ascorbic acid, or its derivatives and/or extracts containing ascorbic acid, from degradation, instability, loss of potency and loss of color.
The topical pharmaceutical delivery vehicle includes a single phase carrier, such as a mixture, dispersion or suspension, of a base consisting essentially of a substantially anhydrous composition, with no water added, in combination with the ascorbic acid, ascorbic acid derivatives and/or extracts containing ascorbic acid, wherein the substantially anhydrous composition, with no water added, is provided in a range of from 0.1 percent by weight to 99.8 percent by weight, preferably about 30 percent by weight.
The present invention does not rely upon an emulsion, and is not limited by the need to solubize Vitamin C
(ascorbic acid) in an aqueous or water miscible phase of an emulsion before proceeding further to try and stabilize ascorbic acid in a second oil phase of the emulsion. For example, standard chemistry, pharmaceutical and cosmetic text books define an emulsion as in Punto '149, in the usual manner. As noted before, Remington's Pharmaceutical Sciences states "an emulsion is a dispersed system containing at least two immiscible liquid phases. The emulsifying agent is added to the system to improve its stability."
Punto '149 makes use of emulsion technology as described in standard textbooks, whereas the single phase carrier of the present invention utilizes a method that does not rely on emulsion technology.
The anhydrous base with a single phase carrier of the present invention teaches a new approach, making it possible to stabilize ascorbic acid without forming an emulsion.
This greatly simplifies product manufacturing and removes many of the logistical and long term stability hindrances associated with emulsions.
Punto '149 uses a "two phase carrier" emulsion in a gelatin capsule. In contrast, the present invention is a simple "single phase carrier" such as a mixture, suspension or dispersion.
In the "background" section of Punto '149, it is stated that ascorbic acid and PEG are in an oil emulsion. Punto '149 solubizes them in an emulsion. In contrast, the present invention forms a single phase carrier suspension.
There is no need to solubize the ascorbic acid, and no need to form emulsion.
For example, in Punto '149, there are two phases:
a primary, solvent or water miscible phase and a secondary, anhydrous oil phase.
In contrast, the present invention does not need an emulsion for improving skin feel and luster. Furthermore, l0 some emulsions are incompatible with an anhydrous base.
In the preferred embodiment, the substantially anhydrous base includes silicone compounds, which provide a unique, cosmetically elegant smooth, lustrous tactile feel when applied to the skin.
Preferably the substantially anhydrous composition, with no water added, includes silicones and derivatives of silicone chemistry. However, other substantially anhydrous compositions, with no water added, may be utilized, such as other emollients, emulsifiers, surfactants, oils and waxes, polyols, binders, polymers, gums, viscosity aids, humectants, anti-oxidants or chelating agents.
Other inactive components may include preservatives, humectants, viscosity control aids, pH buffers and carrier solvents. However, certain pH buffers and solvents may also function as a substantially anhydrous base.
The resultant mixture is a smooth feeling delivery vehicle which delivers the ascorbic acid or its derivatives to the skin in an effective and stable manner.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
In accordance with the present invention, a stable, long-lasting composition is provided as a pharmaceutical delivery vehicle for delivery of ascorbic acid to sun-damaged and photo-aged skin.
A method of treating photo-aged skin, sunburn, wrinkles, dark or uneven pigmentation and related skin disorders is also provided by topical application of a lotion, cream, gel or pad applied formulation, preferably a composition with substantially anhydrous base in the form of a single phase carrier, such as a mixture, suspension or dispersion, composition, with no water added, containing effective amounts of a compound selected from the group consisting of ascorbic acid, ascorbic acid derivatives and/or extracts containing ascorbic acid, for topical application to the affected area of the skin.
In use as a topical agent, ascorbic acid, or its derivatives, such as ascorbyl palmitate, sodium ascorbate, potassium ascorbate, ammonium ascorbate, triethanolamine ascorbate, ascorbyl phosphate or magnesium ascorbyl phosphate, ascorbic acid polypeptides, ascorbyl glucosamine, ascorbic acid polymers, esters of ascorbic acid, amides of ascorbic acid, L-ascorbic acid, known as vitamin C, or other derivatives, or related compounds, including botanical or herbal extracts, such as extract of acerola, citrus extracts, strawberry, which may supply L-ascorbic acid or its derivatives, is topically applied to the skin of a user in a pharmaceutically acceptable vehicle, in a concentration of from 0.1 percent by weight to 95 percent by weight, preferably 10-15 percent by weight, generally by frequent periodic application, such as by a once or twice daily application.
Instead of a water based delivery system, or multiphase system in which a water miscible phase is utilized, the compound containing ascorbic acid, ascorbic acid derivatives and/or extracts containing ascorbic acid, is provided in a substantially anhydrous with no water added base. The base provides a unique cosmetically, elegant topical vehicle which protects the ascorbic acid or its derivatives from degradation, instability, loss of potency and loss of color.
The base includes a single phase carrier, such as a mixture of a substantially anhydrous composition, with no water added, with the compound, instead of a two phase emulsion carrier, wherein the substantially anhydrous composition is provided in a range of from 0.1 percent by weight to 99.8 percent by weight, preferably about 30-45 percent.
Preferably the substantially anhydrous composition, with no water added, includes silicones and derivatives of silicone chemistry, including but not limited to cyclomethicones (volatile silicones), linear silicones, dimethylpolysiloxane, dimethicone copolyols, silicone glycols, aminofunctional silicones, polymeric silicones, silicon waxes, such as high molecular weight dimethicones and silicone derivative waxes.
When various silicone compounds are used, a lustrous, elegant smooth tactile feel is achieved when the topical composition is applied to the skin.
Other substantially anhydrous compositions, with no water added, may be substituted for the silicones, such as other emollients, including but not limited to esters, amides, ethoxylated fats, mineral oil, petrolatum, vegetable fats and animal fats, such as hydrogenated tallow and lanolin.
Substantially anhydrous synthetic wax blends, such as triglycerides and tribehenin may be utilized. Polyols such as polyhydric alcohols and solvents such as mineral oil, glycerin and propylene glycol and,sorbitol may be used.
Emulsifiers such as anhydrous polysorbate and polyethylene glycol, such as PEG 60 hydrogenated castor oil may be employed, as well as anhydrous surfactants such as nonylphenol.
Anti-oxidants, such as BHA, BHT, propylgallate, Vitamin E tocopherol, as well as chelating agents such as disodium EDTA, may also be used to further stabilize other substantially anhydrous bases. However, liquid or non-granular anti-oxidants, may be used as a substantially anyhydrous base with ascorbic acid by themselves.
Fat soluble vitamins, such as substantially anhydrous Vitamins A, D and E and their esters or derivatives, may also be used as bases for the ascorbic acid based composition.
Moreover, pH buffers such as alkaline sodium citrate and magnesium citrate are effective as substantially anhydrous bases for the delivery vehicle.
Other inactive components may include preservatives, such as phenoxetol, humectants, viscosity control aids, pH
buffers and carrier solvents. However, as noted above, certain pH buffers and solvents may also act as an anhydrous base.
The resultant mixture is a comfortable delivery vehicle which delivers the ascorbic acid, its derivatives or extracts containing ascorbic acid to the skin in an effective and stable manner.
The following examples illustrate topically applied skin care products which can be prepared using conventional procedures from the following ingredients with typical ranges of acceptable percentages by weight and typical preferred percentage by weight shown. The formulations are illustrative only, and the preferred range is about the percentage specified:
Formulation #1:
Ingredient Range(%w/w) Preferred (%w/w) Ascorbic acid 0.1-95.0 About 10.0 Cyclomethicone 0.1-99.8 About 30.0 Water (no water added) 0-5.0 0.0 Surfactant 0-90.0 About 5.0 Methylparaben (preservative) 0.0-3.0 About 0.2 Steareth-2 (emulsifier) 0.0-10.0 About 3.5 Gelene (viscosity aid) 0.0-95.0 About 36.3 Bentonite (binder) 0.0-25.0 About 5.0 Formulation #2:
Ingredient Range(%w/w) Preferred (%w/w) Polyglyceryl methacrylate Gel 0.0-99.0 About 60.0 Ascorbic acid 0.1-95.0 About 15.0 Silicone Gylcol 0.1-60.0 About 15.0 Water 0.0 to balance 0.0 to balance (no water added) of composition of composition It has also been found that the product is more stable if the cyclomethicone is increased up to about 45% by weight, and the viscosity aid, such as gelene, and the binder, such as bentonite, are excluded, as shown in the alternate embodiment shown in Formulation #3 below:
Formulation #3:
Ingredient Range(%w/w) Preferred (%w/w) Ascorbic acid 0.1-95.0 about 5.0 Cyclomethicone 0.1-99.8 about45.0 Water (no water added) 0-5.0 balance of composition Surfactant 0-90.0 ' About 5.0 Phenoxetol (preservative) 0.0-5.0 About 0.5 Dimethicone 0.0-99.8 About 10.0 Other formulations include the following:
l0 Formulation ~4:
Ingredient Range(%w/w) Preferred (%w/w) Ascorbic acid 0.1-99.8 About 10.0 Petrolatum 0.1-99.8 About 90.0 Formulation ~5:
Ingredient Range(%w/w) Preferred (%w/w) Hydrogenated vegetable shortening 0.1-99.8 About 90.0 Ascorbic acid 0.1-99.8 About 10.0 Formulation ~6:
Ingredient Range(%w/w) Preferred (%w/w) Cyclomethicone and dimethicone blend 0.0-99.8 About 70.0 Ascorbic acid 0.1-99.8 About 15.0 Cyclomethicone 0.1-99.8 About 10.0 Dimethicone 0.1-99.8 About 15.0 The composition is made in a single phase, wherein the single phase carrier is an anhydrous base, which is mixed with the ascorbic acid by mixing, dispersing or by suspension, according to techniques known to those skilled in the art. No separate emulsion phases are needed.
The present invention therefore includes a method for the prevention and/or treatment of photo-aged skin and related skin disorders, such as wrinkles, sunburn, poor skin tone and skin discoloration.
The method comprises steps of the topical application of suitable compositions containing stable ascorbic acid, its derivatives or extracts containing ascorbic acid, in a single phase, substantially anhydrous base, with no water added.
In general, the treatment composition suitable for use in accordance with the invention containing ascorbic acid, its derivatives or extracts containing ascorbic acid, may be applied in any dermatologically acceptable vehicle such as a gel, lotion, cream, stick, spray, serum, or pad applied formulation, which may or may not be emulsified and may contain ingredients to improve, modify, or stabilize the formulation physically or cosmetically. Other suitable formulations will be apparent to those skilled in the art.
The treatment compositions of the invention will improve the condition of the skin to which it is applied, preferably by frequent periodical application over an extended period of time without undue irritation to the skin or any other side effects.
Generally, the topical applications are applied periodically such as one or two times per day.
Moreover, Table 1 shows the stability of examples of the composition. Stability tests were conducted of topical skin treatment compositions containing ascorbic acid, specifically L-ascorbic acid at 10%. The compositions were tested for percentage of stability as a function of shelf life in a closed jar at either room temperature or at an elevated temperature of from 40°C to 45°C. Tests of the containers of the compositions at room temperature were conducted over a six month period and tests of the containers of the compositions at elevated temperature of from 40°C to 45°C were conducted over a three month period.
Table I
Compo sition No. 1: a topical facial complex ning 10$ of contai L-asc orbic acid.
a) Condition: maintained at room temperaturea ~ oz. clear in jar with lined cap.
b) Test: ascorbic acid assay.
c) Recommended Percentage of Stability: 110.0 80.0 -d) Resultant Percentage of Stability:
0 months 3 months 6 months 95.6$ 90.1$ 90.4$
Compo sition No. 1: a topical facial complex ning 10$ of contai L-ascorbic acid.
a) Condition: maintained at 40C to 45C oz. clear jar in a ~ with lined cap.
15b) Test: ascorbic acid assay.
c) Recommended Percentage of Stability: 110.0$
80.0$ -d) Resultant Percentage of Stability:
0 months 1 month 2 months 3 months 95.6$ 91.4 90.4$ 84.5 20Composition containing 10$
No. of 2:
a topical hand and body complex L-ascorbic acid.
a) Condition: maintained at room temperaturea 2 oz. container.
in b) Test: ascorbic acid assay.
c) Recommended Percentage of Stability: 110.0$
80.0$ -' 25d) Resultant Percentage of Stability:
0 months 3 months 6 months 98.5$ 92.4$ 90.2$
Composition containing 10$
No. of 2:
a topical hand and body complex L-ascorbic acid.
30a) Condition: maintained at elevated temperature from 40C to 45C
in a 2 oz. container.
b) Test: ascorbic acid assay.
c) Recommended Percentage of Stability: 110.0$
80.0 -d) Resultant Percentage of Stability:
35 0 months 1 month 2 month 3 months 98.5$ 95.0$ 91.1$ 84.0$
The aforesaid formulations are merely illustrative of the general concepts. Other changes to the present invention may be made without departing from the spirit or scope thereof, when read in conjunction with the appended claims.
Ascorbic acid, or its derivatives, such as ascorbic palmitate, sodium ascorbate, potassium ascorbate, ammonium ascorbate, triethanolamine ascorbate, ascorbyl phosphate or magnesium ascorbyl phosphate and related compounds, is applied in a pharmaceutically acceptable vehicle, in a concentration of from 0.1 percent by weight to 95 percent by weight, preferably 10-15 percent by weight, generally by frequent periodic application, such as by a once or twice daily application.
Instead of a substantially water based delivery system, the ascorbic acid, ascorbic acid derivatives and/or extracts containing ascorbic acid are provided in a substantially anhydrous base, with no added water. Because one or more of the components may have a natural water sub-component, the base is not water free, but is substantially anhydrous, because the pre-existing water concentration does not generally exceed five (5) percent by weight of the total composition. To achieve the substantially anhydrous composition, no water is added, in contrast to the water-based composition in Darr '043.
The substantially anhydrous base protects the ascorbic acid, or its derivatives and/or extracts containing ascorbic acid, from degradation, instability, loss of potency and loss of color.
The topical pharmaceutical delivery vehicle includes a single phase carrier, such as a mixture, dispersion or suspension, of a base consisting essentially of a substantially anhydrous composition, with no water added, in combination with the ascorbic acid, ascorbic acid derivatives and/or extracts containing ascorbic acid, wherein the substantially anhydrous composition, with no water added, is provided in a range of from 0.1 percent by weight to 99.8 percent by weight, preferably about 30 percent by weight.
The present invention does not rely upon an emulsion, and is not limited by the need to solubize Vitamin C
(ascorbic acid) in an aqueous or water miscible phase of an emulsion before proceeding further to try and stabilize ascorbic acid in a second oil phase of the emulsion. For example, standard chemistry, pharmaceutical and cosmetic text books define an emulsion as in Punto '149, in the usual manner. As noted before, Remington's Pharmaceutical Sciences states "an emulsion is a dispersed system containing at least two immiscible liquid phases. The emulsifying agent is added to the system to improve its stability."
Punto '149 makes use of emulsion technology as described in standard textbooks, whereas the single phase carrier of the present invention utilizes a method that does not rely on emulsion technology.
The anhydrous base with a single phase carrier of the present invention teaches a new approach, making it possible to stabilize ascorbic acid without forming an emulsion.
This greatly simplifies product manufacturing and removes many of the logistical and long term stability hindrances associated with emulsions.
Punto '149 uses a "two phase carrier" emulsion in a gelatin capsule. In contrast, the present invention is a simple "single phase carrier" such as a mixture, suspension or dispersion.
In the "background" section of Punto '149, it is stated that ascorbic acid and PEG are in an oil emulsion. Punto '149 solubizes them in an emulsion. In contrast, the present invention forms a single phase carrier suspension.
There is no need to solubize the ascorbic acid, and no need to form emulsion.
For example, in Punto '149, there are two phases:
a primary, solvent or water miscible phase and a secondary, anhydrous oil phase.
In contrast, the present invention does not need an emulsion for improving skin feel and luster. Furthermore, l0 some emulsions are incompatible with an anhydrous base.
In the preferred embodiment, the substantially anhydrous base includes silicone compounds, which provide a unique, cosmetically elegant smooth, lustrous tactile feel when applied to the skin.
Preferably the substantially anhydrous composition, with no water added, includes silicones and derivatives of silicone chemistry. However, other substantially anhydrous compositions, with no water added, may be utilized, such as other emollients, emulsifiers, surfactants, oils and waxes, polyols, binders, polymers, gums, viscosity aids, humectants, anti-oxidants or chelating agents.
Other inactive components may include preservatives, humectants, viscosity control aids, pH buffers and carrier solvents. However, certain pH buffers and solvents may also function as a substantially anhydrous base.
The resultant mixture is a smooth feeling delivery vehicle which delivers the ascorbic acid or its derivatives to the skin in an effective and stable manner.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
In accordance with the present invention, a stable, long-lasting composition is provided as a pharmaceutical delivery vehicle for delivery of ascorbic acid to sun-damaged and photo-aged skin.
A method of treating photo-aged skin, sunburn, wrinkles, dark or uneven pigmentation and related skin disorders is also provided by topical application of a lotion, cream, gel or pad applied formulation, preferably a composition with substantially anhydrous base in the form of a single phase carrier, such as a mixture, suspension or dispersion, composition, with no water added, containing effective amounts of a compound selected from the group consisting of ascorbic acid, ascorbic acid derivatives and/or extracts containing ascorbic acid, for topical application to the affected area of the skin.
In use as a topical agent, ascorbic acid, or its derivatives, such as ascorbyl palmitate, sodium ascorbate, potassium ascorbate, ammonium ascorbate, triethanolamine ascorbate, ascorbyl phosphate or magnesium ascorbyl phosphate, ascorbic acid polypeptides, ascorbyl glucosamine, ascorbic acid polymers, esters of ascorbic acid, amides of ascorbic acid, L-ascorbic acid, known as vitamin C, or other derivatives, or related compounds, including botanical or herbal extracts, such as extract of acerola, citrus extracts, strawberry, which may supply L-ascorbic acid or its derivatives, is topically applied to the skin of a user in a pharmaceutically acceptable vehicle, in a concentration of from 0.1 percent by weight to 95 percent by weight, preferably 10-15 percent by weight, generally by frequent periodic application, such as by a once or twice daily application.
Instead of a water based delivery system, or multiphase system in which a water miscible phase is utilized, the compound containing ascorbic acid, ascorbic acid derivatives and/or extracts containing ascorbic acid, is provided in a substantially anhydrous with no water added base. The base provides a unique cosmetically, elegant topical vehicle which protects the ascorbic acid or its derivatives from degradation, instability, loss of potency and loss of color.
The base includes a single phase carrier, such as a mixture of a substantially anhydrous composition, with no water added, with the compound, instead of a two phase emulsion carrier, wherein the substantially anhydrous composition is provided in a range of from 0.1 percent by weight to 99.8 percent by weight, preferably about 30-45 percent.
Preferably the substantially anhydrous composition, with no water added, includes silicones and derivatives of silicone chemistry, including but not limited to cyclomethicones (volatile silicones), linear silicones, dimethylpolysiloxane, dimethicone copolyols, silicone glycols, aminofunctional silicones, polymeric silicones, silicon waxes, such as high molecular weight dimethicones and silicone derivative waxes.
When various silicone compounds are used, a lustrous, elegant smooth tactile feel is achieved when the topical composition is applied to the skin.
Other substantially anhydrous compositions, with no water added, may be substituted for the silicones, such as other emollients, including but not limited to esters, amides, ethoxylated fats, mineral oil, petrolatum, vegetable fats and animal fats, such as hydrogenated tallow and lanolin.
Substantially anhydrous synthetic wax blends, such as triglycerides and tribehenin may be utilized. Polyols such as polyhydric alcohols and solvents such as mineral oil, glycerin and propylene glycol and,sorbitol may be used.
Emulsifiers such as anhydrous polysorbate and polyethylene glycol, such as PEG 60 hydrogenated castor oil may be employed, as well as anhydrous surfactants such as nonylphenol.
Anti-oxidants, such as BHA, BHT, propylgallate, Vitamin E tocopherol, as well as chelating agents such as disodium EDTA, may also be used to further stabilize other substantially anhydrous bases. However, liquid or non-granular anti-oxidants, may be used as a substantially anyhydrous base with ascorbic acid by themselves.
Fat soluble vitamins, such as substantially anhydrous Vitamins A, D and E and their esters or derivatives, may also be used as bases for the ascorbic acid based composition.
Moreover, pH buffers such as alkaline sodium citrate and magnesium citrate are effective as substantially anhydrous bases for the delivery vehicle.
Other inactive components may include preservatives, such as phenoxetol, humectants, viscosity control aids, pH
buffers and carrier solvents. However, as noted above, certain pH buffers and solvents may also act as an anhydrous base.
The resultant mixture is a comfortable delivery vehicle which delivers the ascorbic acid, its derivatives or extracts containing ascorbic acid to the skin in an effective and stable manner.
The following examples illustrate topically applied skin care products which can be prepared using conventional procedures from the following ingredients with typical ranges of acceptable percentages by weight and typical preferred percentage by weight shown. The formulations are illustrative only, and the preferred range is about the percentage specified:
Formulation #1:
Ingredient Range(%w/w) Preferred (%w/w) Ascorbic acid 0.1-95.0 About 10.0 Cyclomethicone 0.1-99.8 About 30.0 Water (no water added) 0-5.0 0.0 Surfactant 0-90.0 About 5.0 Methylparaben (preservative) 0.0-3.0 About 0.2 Steareth-2 (emulsifier) 0.0-10.0 About 3.5 Gelene (viscosity aid) 0.0-95.0 About 36.3 Bentonite (binder) 0.0-25.0 About 5.0 Formulation #2:
Ingredient Range(%w/w) Preferred (%w/w) Polyglyceryl methacrylate Gel 0.0-99.0 About 60.0 Ascorbic acid 0.1-95.0 About 15.0 Silicone Gylcol 0.1-60.0 About 15.0 Water 0.0 to balance 0.0 to balance (no water added) of composition of composition It has also been found that the product is more stable if the cyclomethicone is increased up to about 45% by weight, and the viscosity aid, such as gelene, and the binder, such as bentonite, are excluded, as shown in the alternate embodiment shown in Formulation #3 below:
Formulation #3:
Ingredient Range(%w/w) Preferred (%w/w) Ascorbic acid 0.1-95.0 about 5.0 Cyclomethicone 0.1-99.8 about45.0 Water (no water added) 0-5.0 balance of composition Surfactant 0-90.0 ' About 5.0 Phenoxetol (preservative) 0.0-5.0 About 0.5 Dimethicone 0.0-99.8 About 10.0 Other formulations include the following:
l0 Formulation ~4:
Ingredient Range(%w/w) Preferred (%w/w) Ascorbic acid 0.1-99.8 About 10.0 Petrolatum 0.1-99.8 About 90.0 Formulation ~5:
Ingredient Range(%w/w) Preferred (%w/w) Hydrogenated vegetable shortening 0.1-99.8 About 90.0 Ascorbic acid 0.1-99.8 About 10.0 Formulation ~6:
Ingredient Range(%w/w) Preferred (%w/w) Cyclomethicone and dimethicone blend 0.0-99.8 About 70.0 Ascorbic acid 0.1-99.8 About 15.0 Cyclomethicone 0.1-99.8 About 10.0 Dimethicone 0.1-99.8 About 15.0 The composition is made in a single phase, wherein the single phase carrier is an anhydrous base, which is mixed with the ascorbic acid by mixing, dispersing or by suspension, according to techniques known to those skilled in the art. No separate emulsion phases are needed.
The present invention therefore includes a method for the prevention and/or treatment of photo-aged skin and related skin disorders, such as wrinkles, sunburn, poor skin tone and skin discoloration.
The method comprises steps of the topical application of suitable compositions containing stable ascorbic acid, its derivatives or extracts containing ascorbic acid, in a single phase, substantially anhydrous base, with no water added.
In general, the treatment composition suitable for use in accordance with the invention containing ascorbic acid, its derivatives or extracts containing ascorbic acid, may be applied in any dermatologically acceptable vehicle such as a gel, lotion, cream, stick, spray, serum, or pad applied formulation, which may or may not be emulsified and may contain ingredients to improve, modify, or stabilize the formulation physically or cosmetically. Other suitable formulations will be apparent to those skilled in the art.
The treatment compositions of the invention will improve the condition of the skin to which it is applied, preferably by frequent periodical application over an extended period of time without undue irritation to the skin or any other side effects.
Generally, the topical applications are applied periodically such as one or two times per day.
Moreover, Table 1 shows the stability of examples of the composition. Stability tests were conducted of topical skin treatment compositions containing ascorbic acid, specifically L-ascorbic acid at 10%. The compositions were tested for percentage of stability as a function of shelf life in a closed jar at either room temperature or at an elevated temperature of from 40°C to 45°C. Tests of the containers of the compositions at room temperature were conducted over a six month period and tests of the containers of the compositions at elevated temperature of from 40°C to 45°C were conducted over a three month period.
Table I
Compo sition No. 1: a topical facial complex ning 10$ of contai L-asc orbic acid.
a) Condition: maintained at room temperaturea ~ oz. clear in jar with lined cap.
b) Test: ascorbic acid assay.
c) Recommended Percentage of Stability: 110.0 80.0 -d) Resultant Percentage of Stability:
0 months 3 months 6 months 95.6$ 90.1$ 90.4$
Compo sition No. 1: a topical facial complex ning 10$ of contai L-ascorbic acid.
a) Condition: maintained at 40C to 45C oz. clear jar in a ~ with lined cap.
15b) Test: ascorbic acid assay.
c) Recommended Percentage of Stability: 110.0$
80.0$ -d) Resultant Percentage of Stability:
0 months 1 month 2 months 3 months 95.6$ 91.4 90.4$ 84.5 20Composition containing 10$
No. of 2:
a topical hand and body complex L-ascorbic acid.
a) Condition: maintained at room temperaturea 2 oz. container.
in b) Test: ascorbic acid assay.
c) Recommended Percentage of Stability: 110.0$
80.0$ -' 25d) Resultant Percentage of Stability:
0 months 3 months 6 months 98.5$ 92.4$ 90.2$
Composition containing 10$
No. of 2:
a topical hand and body complex L-ascorbic acid.
30a) Condition: maintained at elevated temperature from 40C to 45C
in a 2 oz. container.
b) Test: ascorbic acid assay.
c) Recommended Percentage of Stability: 110.0$
80.0 -d) Resultant Percentage of Stability:
35 0 months 1 month 2 month 3 months 98.5$ 95.0$ 91.1$ 84.0$
The aforesaid formulations are merely illustrative of the general concepts. Other changes to the present invention may be made without departing from the spirit or scope thereof, when read in conjunction with the appended claims.
Claims (50)
1. A topical composition comprising a compound selected from the group consisting of ascorbic acid, derivatives of ascorbic acid and extracts containing ascorbic acid, said compound being provided in a substantially anhydrous single phase carrier pharmaceutically acceptable base.
2. The topical composition as in Clain 1 wherein said substantially anhydrous single phase carrier is a water immiscible carrier.
3. The composition as in Claim 1 wherein said compound is provided in a percent by weight of the total composition of from 0.1-95 percent by weight.
4. The composition as in Claim 1 wherein said compound is provided in a percent by weight of the total composition of about 10-15 percent by weight.
5. The composition as in Claim 1 wherein said substantially anhydrous base is provided in a percent by weight of the total composition of from 0.1 - 99.8 percent by weight.
6. The composition as in Claim 5 wherein said substantially anhydrous base is provided in a percent by weight of the total composition of about 45 percent by weight.
7. The composition as in Claim 1 wherein said substantially anhydrous base comprises a silicone.
8. The composition as in Claim 7 wherein said substantially anhydrous base comprises a cyclomethicone.
9. The composition as in Claim 7 wherein said substantially anhydrous base comprises a linear silicone.
10. The composition as in Claim 7 wherein said substantially anhydrous base comprises dimethylpolysiloxane.
11. The composition as in Claim 7 wherein said substantially anhydrous base comprises a dimethicone copolyol.
12. The composition as in Claim 7 wherein said substantially anhydrous base comprises a silicone glycol.
13. The composition as in Claim 7 wherein said substantially anhydrous base comprises an aminofunctional silicone.
14. The composition as in Claim 7 wherein said substantially anhydrous base comprises an polymeric silicone.
15. The composition as in Claim 1 wherein said substantially anhydrous base comprises an emollient.
16. The composition as in Claim 1 wherein said substantially anhydrous base comprises an emulsifier.
17. The composition as in Claim 1 wherein said substantially anhydrous base comprises a surfactant.
18. The composition as in Claim 1 wherein said substantially anhydrous base comprises a liquid anti-oxidant.
19. The composition as in Claim 1 wherein said substantially anhydrous base comprises a chelating agent.
20. The composition as in Claim 1 wherein said substantially anhydrous base comprises a solvent.
21. The composition as in Claim 1 wherein said substantially anhydrous base comprises a synthetic wax.
22. The composition as in Claim 1 wherein said substantially anhydrous base comprises an alkaline anhydrous pH buffer.
23. The composition as in Claim 1 wherein said substantially anhydrous base comprises a fat soluble vitamin.
24. The composition as in Claim 1 wherein said substantially anhydrous base comprises a polymer.
25. The composition as in Claim 1 wherein said substantially anhydrous base comprises a gum.
26. The composition as in Claim 1 wherein said substantially anhydrous base comprises a humectant.
27. The composition of Claim 1 wherein said compound is ascorbic acid being provided of from about 10 to about 15 percent by weight of the composition and wherein said substantially anhydrous base is cyclomethicone being provided at about 45 percent by weight of the composition.
28 The composition of Claim 1 wherein said compound is ascorbic acid being provided at from about 0.1 to about percent weight of the composition and wherein said substantially anhydrous base is cyclomethicone being provided at about 45 percent by weight of the composition.
29. The composition of Claim 1 wherein said compound is ascorbic acid being provided at about 10 to 15 percent by weight of the composition and wherein said substantially anhydrous base is cyclomethicone being provided at about 45 percent by weight of the composition.
30. The composition of Claim 1 wherein said compound is ascorbic acid being provided at about 10 to 15 percent by weight of the composition and wherein said substantially anhydrous base includes cyclomethicone and dimethicone.
31. The composition of Claim 1 according to the following, where components are provided in a percent by weight of the total composition:
Formulation #1:
Ingredient Range(%w/w) Ascorbic acid 0.1-95.0 Cyclomethicone 0.1-99.8 Water (no water added) 0-5.0 Surfactant 0-90.0 Methylparaben (preservative) 0.0-3.0 Steareth-2 (emulsifier) 0.0-10.0 Gelene (viscosity aid) 0.0-95.0 Bentonite (binder) 0.0-25.0
Formulation #1:
Ingredient Range(%w/w) Ascorbic acid 0.1-95.0 Cyclomethicone 0.1-99.8 Water (no water added) 0-5.0 Surfactant 0-90.0 Methylparaben (preservative) 0.0-3.0 Steareth-2 (emulsifier) 0.0-10.0 Gelene (viscosity aid) 0.0-95.0 Bentonite (binder) 0.0-25.0
32. The composition of Claim 1 according to the following, where components are provided in a percent by weight of the total composition:
Formulation #1:
Ingredient Range(%w/w) Ascorbic acid about 10.0 Cyclomethicone about 30.0 Water (no water added) 0.0 to balance of composition Surfactant about 5.0 Methylparaben (preservative) about 0.2 Steareth-2 (emulsifier) about 3.5 Gelene (viscosity aid) about 36.3 Bentonite (binder) about 5.0
Formulation #1:
Ingredient Range(%w/w) Ascorbic acid about 10.0 Cyclomethicone about 30.0 Water (no water added) 0.0 to balance of composition Surfactant about 5.0 Methylparaben (preservative) about 0.2 Steareth-2 (emulsifier) about 3.5 Gelene (viscosity aid) about 36.3 Bentonite (binder) about 5.0
33. The composition of Claim 1 according to the following, where components are provided in a percent by weight of the total composition:
Formulation #2:
Ingredient Range(%w/w) Polyglyceryl methacrylate Gel 0.0-99.0 Ascorbic acid 0.1-95.0 Silicone Gylcol 0.1-60.0 Water (no water added)0.0 to balance of composition
Formulation #2:
Ingredient Range(%w/w) Polyglyceryl methacrylate Gel 0.0-99.0 Ascorbic acid 0.1-95.0 Silicone Gylcol 0.1-60.0 Water (no water added)0.0 to balance of composition
34. The composition of Claim 1 according to the following, where components are provided in a percent by weight of the total composition:
Formulation #2:
Ingredient Range(%w/w) Polyglyceryl methacrylate Gel about 60.0 Ascorbic acid about 15.0 Silicone Gylcol about 15.0 Water (no water added) 0.0 to balance of composition
Formulation #2:
Ingredient Range(%w/w) Polyglyceryl methacrylate Gel about 60.0 Ascorbic acid about 15.0 Silicone Gylcol about 15.0 Water (no water added) 0.0 to balance of composition
35. The composition of Claim 1 according to the following, where components are provided in a percent by weight of the total composition:
Formulation #3:
Ingredient Range(%w/w) Ascorbic acid 0.1-95.0 Cyclomethicone 0.1-99.8 Water (no water added 0-5.0 balance of composition Surfactant 0-90.0 Phenoxetol (preservative) 0.0-5.0 Dimethicone 0.0-99.8
Formulation #3:
Ingredient Range(%w/w) Ascorbic acid 0.1-95.0 Cyclomethicone 0.1-99.8 Water (no water added 0-5.0 balance of composition Surfactant 0-90.0 Phenoxetol (preservative) 0.0-5.0 Dimethicone 0.0-99.8
36. The composition of Claim 1 according to the following, where components are provided in a percent by weight of the total composition:
Formulation #3:
Ingredient Range(%w/w) Ascorbic acid about 5.0 Cyclomethicone about 45.0 Water (no water added balance of composition Surfactant about 5.0 Phenoxetol (preservative) about 0.5 Dimethicone about 10.0
Formulation #3:
Ingredient Range(%w/w) Ascorbic acid about 5.0 Cyclomethicone about 45.0 Water (no water added balance of composition Surfactant about 5.0 Phenoxetol (preservative) about 0.5 Dimethicone about 10.0
37. The composition of Claim 1 according to the following, where components are provided in a percent by weight of the total composition:
Formulation #4:
Ingredient Range(%w/w) Ascorbic acid 0.1-99.8 Petrolatum 0.1-99.8
Formulation #4:
Ingredient Range(%w/w) Ascorbic acid 0.1-99.8 Petrolatum 0.1-99.8
38. The composition of Claim 1 according to the following, where components are provided in a percent by weight of the total composition:
Formulation #4:
Ingredient Range(%w/w) Ascorbic acid about 10.0 Petrolatum about 90.0
Formulation #4:
Ingredient Range(%w/w) Ascorbic acid about 10.0 Petrolatum about 90.0
39. The composition of Claim 1 according to the following, where components are provided in a percent by weight of the total composition:
Formulation #5:
Ingredient Range(%w/w) Hydrogenated vegetable shortening 0.1-99.8 Ascorbic acid 0.1-99.8
Formulation #5:
Ingredient Range(%w/w) Hydrogenated vegetable shortening 0.1-99.8 Ascorbic acid 0.1-99.8
40. The composition of Claim 1 according to the following, where components are provided in a percent by weight of the total composition:
Formulation #5:
Ingredient Range(%w/w) Hydrogenated vegetable shortening about 90.0 Ascorbic acid about 10.0
Formulation #5:
Ingredient Range(%w/w) Hydrogenated vegetable shortening about 90.0 Ascorbic acid about 10.0
41. The composition of Claim 1 according to the following, where components are provided in a percent by weight of the total composition:
Formulation #6:
Ingredient Range(%w/w) Cyclomethicone and dimethicone blend 0.0-99.8 Ascorbic acid 0.1-99.8 Cyclomethicone 0.1-99.8 Dimethicone 0.1-99.8
Formulation #6:
Ingredient Range(%w/w) Cyclomethicone and dimethicone blend 0.0-99.8 Ascorbic acid 0.1-99.8 Cyclomethicone 0.1-99.8 Dimethicone 0.1-99.8
42. The composition of Claim 1 according to the following, where components are provided in a percent by weight of the total composition:
Formulation #6:
Ingredient Range(%w/w) Cyclomethicone and dimethicone blend about 70.0 Ascorbic acid about 15.0 Cyclomethicone about 10.0 Dimethicone about 15.0
Formulation #6:
Ingredient Range(%w/w) Cyclomethicone and dimethicone blend about 70.0 Ascorbic acid about 15.0 Cyclomethicone about 10.0 Dimethicone about 15.0
43. A method of treating photo-aged skin and related skin disorders, such as wrinkles, dark or uneven pigmentation, sunburn, poor skin tone and skin discoloration, comprising the steps of applying topically to the area of the skin affected an effective amount of a treatment composition comprising a compound selected from the group consisting of ascorbic acid, derivatives of ascorbic acid and extracts containing ascorbic acid, said compound being provided in a concentration of from 0.1 to about 95 percent by weight of said treatment composition, wherein said treatment composition is applied in a pharmaceutically acceptable vehicle comprising a single phase carrier substantially anhydrous base.
44. The method according to Claim 43, wherein said treatment composition is applied periodically to the skin area to be treated, said periodic.treatment being applied at least once a day.
45. The method according to Claim 43, wherein said pharmaceutically acceptable vehicle including the substantially anhydrous base is provided in the group consisting of a cream, lotion, pad applied formulation or gel base.
46. A method of preventing photo-aged skin and related skin disorders, such as wrinkles, dark or uneven pigmentation, sunburn, poor skin tone and skin discoloration, comprising the steps of applying topically to the area of the skin affected an effective amount of a treatment composition comprising a compound selected from the group consisting of ascorbic acid, derivatives of ascorbic acid and extracts containing ascorbic acid, said compound being provided in a concentration of from 0.1 to about 95 percent by weight of said treatment composition, wherein said treatment composition is applied in a pharmaceutically acceptable vehicle comprising a single phase carrier substantially anhydrous base.
47. The method according to Claim 46, wherein said treatment composition is applied periodically to the skin area to be treated, said periodic treatment being applied at least once a day.
48. The method according to Claim 46, wherein said pharmaceutically acceptable vehicle including the substantially anhydrous base is provided in the group consisting of a cream, lotion, pad applied formulation and gel base.
49. Use of the composition of any one of claims 1 to 42 for treating photo-aged skin and related skin disorders.
50. Use of the composition of any one of claims 1 to 42 for preventing photo-aged skin and related skin disorders.
Priority Applications (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/796,784 US5843411A (en) | 1997-02-06 | 1997-02-06 | Stabilization of ascorbic acid, ascorbic acid derivatives and/or extracts containing ascorbic acid for topical use |
| KR1019980043559A KR20000026159A (en) | 1997-02-06 | 1998-10-15 | Method for stabilizing an ascorbic acid, its derivatives and/or extract containing ascorbic acid for local application |
| CA002251414A CA2251414A1 (en) | 1997-02-06 | 1998-10-16 | Stabilization of ascorbic acid, ascorbic acid derivatives and/or extracts containing ascorbic acid for topical use |
| AU89455/98A AU8945598A (en) | 1997-02-06 | 1998-10-21 | Stabilization of ascorbic acid, ascorbic acid derivatives and/or extracts con taining ascorbic acid for topical use |
| US09/725,980 USRE38623E1 (en) | 1996-02-09 | 2000-11-29 | Stabilization of ascorbic acid, ascorbic acid derivatives and/or extracts containing ascorbic acid for topical use |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/796,784 US5843411A (en) | 1997-02-06 | 1997-02-06 | Stabilization of ascorbic acid, ascorbic acid derivatives and/or extracts containing ascorbic acid for topical use |
| KR1019980043559A KR20000026159A (en) | 1997-02-06 | 1998-10-15 | Method for stabilizing an ascorbic acid, its derivatives and/or extract containing ascorbic acid for local application |
| CA002251414A CA2251414A1 (en) | 1997-02-06 | 1998-10-16 | Stabilization of ascorbic acid, ascorbic acid derivatives and/or extracts containing ascorbic acid for topical use |
| AU89455/98A AU8945598A (en) | 1997-02-06 | 1998-10-21 | Stabilization of ascorbic acid, ascorbic acid derivatives and/or extracts con taining ascorbic acid for topical use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2251414A1 true CA2251414A1 (en) | 2000-04-16 |
Family
ID=31999271
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002251414A Abandoned CA2251414A1 (en) | 1996-02-09 | 1998-10-16 | Stabilization of ascorbic acid, ascorbic acid derivatives and/or extracts containing ascorbic acid for topical use |
Country Status (4)
| Country | Link |
|---|---|
| US (2) | US5843411A (en) |
| KR (1) | KR20000026159A (en) |
| AU (1) | AU8945598A (en) |
| CA (1) | CA2251414A1 (en) |
Families Citing this family (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6194452B1 (en) | 1997-11-07 | 2001-02-27 | Howard Murad | Stable pharmaceutical compositions including ascorbic acid and methods of using same |
| US6110966A (en) * | 1998-02-20 | 2000-08-29 | Medi-Cell Laboratories, Inc. | Triple action complex |
| HUP0101070A2 (en) * | 1998-03-12 | 2001-07-30 | The Procter & Gamble Co. | Disposable absorbent article having a skin care composition containing an enzyme inhibitor |
| US6146664A (en) * | 1998-07-10 | 2000-11-14 | Shaklee Corporation | Stable topical ascorbic acid compositions |
| DE19925499A1 (en) * | 1999-06-04 | 2000-12-07 | Beiersdorf Ag | Use of ascorbic acid and one or more flavone derivatives and / or flavonone derivatives, in particular flavonoids, for the preparation of cosmetic or dermatological preparations for the prophylaxis or relief of sunburn |
| US6087393A (en) | 1999-06-10 | 2000-07-11 | Igen, Inc. | Stabilized vitamin C formulations |
| EP1408924A1 (en) * | 1999-07-08 | 2004-04-21 | International Flora Technologies Ltd. | Stabilized ascorbic acid, composition, and method of use |
| US6190645B1 (en) | 1999-07-15 | 2001-02-20 | Playtex Products, Inc. | Sunscreen for the scalp hair and hair |
| FR2800073B1 (en) * | 1999-10-26 | 2001-11-23 | Oreal | NOVEL SILICATED COMPOUNDS DERIVED FROM ASCORBIC ACID, PROCESS FOR THEIR PREPARATION, COMPOSITIONS COMPRISING SAME AND USES THEREOF |
| WO2001066092A1 (en) * | 2000-03-03 | 2001-09-13 | Australian Importers, Ltd. | Micronized vitamin c formulation |
| US7101563B1 (en) * | 2000-03-03 | 2006-09-05 | Australian Importers, Ltd. | Micronized vitamin C formulation |
| US8512718B2 (en) | 2000-07-03 | 2013-08-20 | Foamix Ltd. | Pharmaceutical composition for topical application |
| AU2001286578A1 (en) * | 2000-08-24 | 2002-03-04 | Tim Ioannides | Topical antioxidant having vitamin c and method of combination with topical agent by user |
| US6830746B2 (en) | 2001-09-21 | 2004-12-14 | Playtex Products, Inc. | Sunscreen compositions |
| DE10158447B4 (en) * | 2001-11-30 | 2005-02-10 | Aquanova German Solubilisate Technologies (Agt) Gmbh | Ascorbic Solubilisate |
| KR20030048725A (en) * | 2001-12-13 | 2003-06-25 | 바이오스펙트럼 주식회사 | Production of stabilized ascorbic acid capsules and its use for cosmetics |
| US7314634B2 (en) * | 2002-02-22 | 2008-01-01 | Steven Hernandez | Use of polyphenols to treat skin conditions |
| KR100477716B1 (en) * | 2002-03-19 | 2005-03-18 | 바이오스펙트럼 주식회사 | Method for producing a cosmetic composition containing L-ascorbic acid |
| US20040034094A1 (en) * | 2002-08-16 | 2004-02-19 | Gupta Shyam K. | Vitamin C stabilized topical formulation |
| US7419655B2 (en) * | 2002-09-11 | 2008-09-02 | Kimberly-Clark Worldwide, Inc. | Skin care products |
| US20040067890A1 (en) * | 2002-10-04 | 2004-04-08 | Gupta Shyam K. | Ascorbic acid salts of organic bases with enhanced bioavailability for synergictic anti-aging and skin protective cosmetic compositions |
| IL152486A0 (en) | 2002-10-25 | 2003-05-29 | Meir Eini | Alcohol-free cosmetic and pharmaceutical foam carrier |
| US10117812B2 (en) | 2002-10-25 | 2018-11-06 | Foamix Pharmaceuticals Ltd. | Foamable composition combining a polar solvent and a hydrophobic carrier |
| US7820145B2 (en) | 2003-08-04 | 2010-10-26 | Foamix Ltd. | Oleaginous pharmaceutical and cosmetic foam |
| US8486376B2 (en) | 2002-10-25 | 2013-07-16 | Foamix Ltd. | Moisturizing foam containing lanolin |
| US8119150B2 (en) | 2002-10-25 | 2012-02-21 | Foamix Ltd. | Non-flammable insecticide composition and uses thereof |
| US9668972B2 (en) | 2002-10-25 | 2017-06-06 | Foamix Pharmaceuticals Ltd. | Nonsteroidal immunomodulating kit and composition and uses thereof |
| US8119109B2 (en) | 2002-10-25 | 2012-02-21 | Foamix Ltd. | Foamable compositions, kits and methods for hyperhidrosis |
| US7700076B2 (en) | 2002-10-25 | 2010-04-20 | Foamix, Ltd. | Penetrating pharmaceutical foam |
| US9265725B2 (en) | 2002-10-25 | 2016-02-23 | Foamix Pharmaceuticals Ltd. | Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof |
| MXPA05004278A (en) | 2002-10-25 | 2005-10-05 | Foamix Ltd | Cosmetic and pharmaceutical foam. |
| US9211259B2 (en) | 2002-11-29 | 2015-12-15 | Foamix Pharmaceuticals Ltd. | Antibiotic kit and composition and uses thereof |
| US7704518B2 (en) | 2003-08-04 | 2010-04-27 | Foamix, Ltd. | Foamable vehicle and pharmaceutical compositions thereof |
| US8900554B2 (en) | 2002-10-25 | 2014-12-02 | Foamix Pharmaceuticals Ltd. | Foamable composition and uses thereof |
| US20080138296A1 (en) | 2002-10-25 | 2008-06-12 | Foamix Ltd. | Foam prepared from nanoemulsions and uses |
| KR20040040557A (en) * | 2002-11-07 | 2004-05-13 | 나드리화장품주식회사 | Cosmetics composition having anti-wrinkle and anti-aging effect |
| US7575739B2 (en) | 2003-04-28 | 2009-08-18 | Foamix Ltd. | Foamable iodine composition |
| US8486374B2 (en) | 2003-08-04 | 2013-07-16 | Foamix Ltd. | Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses |
| US8795693B2 (en) | 2003-08-04 | 2014-08-05 | Foamix Ltd. | Compositions with modulating agents |
| DE102005057593A1 (en) * | 2005-07-08 | 2007-01-11 | Schwan-Stabilo Cosmetics Gmbh & Co. Kg | Preparation, in particular cosmetic preparation, and their preparation and use |
| US20070077261A1 (en) * | 2005-10-03 | 2007-04-05 | Jerry Zhang | Compositions and method for enhancing the solubility of ascorbic acid using solubilization enhancers |
| US20080260655A1 (en) | 2006-11-14 | 2008-10-23 | Dov Tamarkin | Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses |
| US20080312169A1 (en) * | 2007-03-20 | 2008-12-18 | Clarence Albert Johnson | Cosmetic use of D-ribose |
| US20090197819A1 (en) * | 2007-03-20 | 2009-08-06 | Clarence Albert Johnson | Compositions for improving and repairing skin |
| US8636982B2 (en) | 2007-08-07 | 2014-01-28 | Foamix Ltd. | Wax foamable vehicle and pharmaceutical compositions thereof |
| WO2009069006A2 (en) | 2007-11-30 | 2009-06-04 | Foamix Ltd. | Foam containing benzoyl peroxide |
| WO2010041141A2 (en) | 2008-10-07 | 2010-04-15 | Foamix Ltd. | Oil-based foamable carriers and formulations |
| WO2009072007A2 (en) | 2007-12-07 | 2009-06-11 | Foamix Ltd. | Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof |
| EP2242476A2 (en) | 2008-01-14 | 2010-10-27 | Foamix Ltd. | Poloxamer foamable pharmaceutical compositions with active agents and/or therapeutic cells and uses |
| US20090232750A1 (en) * | 2008-03-13 | 2009-09-17 | St Cyr John A | Compositions for indoor tanning |
| US20120087872A1 (en) | 2009-04-28 | 2012-04-12 | Foamix Ltd. | Foamable Vehicles and Pharmaceutical Compositions Comprising Aprotic Polar Solvents and Uses Thereof |
| WO2011013008A2 (en) | 2009-07-29 | 2011-02-03 | Foamix Ltd. | Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses |
| WO2011013009A2 (en) | 2009-07-29 | 2011-02-03 | Foamix Ltd. | Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses |
| US9849142B2 (en) | 2009-10-02 | 2017-12-26 | Foamix Pharmaceuticals Ltd. | Methods for accelerated return of skin integrity and for the treatment of impetigo |
| MX359879B (en) | 2009-10-02 | 2018-10-12 | Foamix Pharmaceuticals Ltd | Topical tetracycline compositions. |
| US8174881B2 (en) | 2009-11-24 | 2012-05-08 | Micron Technology, Inc. | Techniques for reducing disturbance in a semiconductor device |
| US20120225107A1 (en) * | 2011-03-04 | 2012-09-06 | Caridad Hechavarria | Stable skin and scar treatment composition |
| TW201532621A (en) | 2013-04-22 | 2015-09-01 | Neocutis Sa | Antioxidant compositions and methods of using the same |
| US20160158134A1 (en) * | 2014-12-08 | 2016-06-09 | Jeane Disalvo | Stable Vitamin C System |
| US10398641B2 (en) | 2016-09-08 | 2019-09-03 | Foamix Pharmaceuticals Ltd. | Compositions and methods for treating rosacea and acne |
| US10098832B1 (en) * | 2017-03-31 | 2018-10-16 | L'oreal | Compositions for short and long term benefits for minimizing wrinkles and fine lines |
| KR20230154830A (en) * | 2021-03-30 | 2023-11-09 | 로레알 | Composition for caring for keratinous substances |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4938969A (en) * | 1988-11-14 | 1990-07-03 | Milor Scientific, Ltd. | Method for the treatment of aging or photo-damaged skin |
| US5140043A (en) * | 1989-04-17 | 1992-08-18 | Duke University | Stable ascorbic acid compositions |
| US5587149A (en) * | 1995-02-06 | 1996-12-24 | R.P. Scherer Corporation | Topical application emulsions |
-
1997
- 1997-02-06 US US08/796,784 patent/US5843411A/en not_active Ceased
-
1998
- 1998-10-15 KR KR1019980043559A patent/KR20000026159A/en not_active Application Discontinuation
- 1998-10-16 CA CA002251414A patent/CA2251414A1/en not_active Abandoned
- 1998-10-21 AU AU89455/98A patent/AU8945598A/en not_active Abandoned
-
2000
- 2000-11-29 US US09/725,980 patent/USRE38623E1/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| AU8945598A (en) | 2000-05-04 |
| US5843411A (en) | 1998-12-01 |
| USRE38623E1 (en) | 2004-10-12 |
| KR20000026159A (en) | 2000-05-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6110477A (en) | Stabilization of ascorbic acid, ascorbic acid derivatives and/or extracts containing ascorbic acid for topical use | |
| US5843411A (en) | Stabilization of ascorbic acid, ascorbic acid derivatives and/or extracts containing ascorbic acid for topical use | |
| JP3202173B2 (en) | Stable water / oil / water emulsion containing water-reactive active ingredients for cosmetics and / or dermatology | |
| JP4716567B2 (en) | Improved and stable topical ascorbic acid composition | |
| US6103247A (en) | Composition containing a non-photocatalytic metal oxide and tocopherol, its use in the cosmetics and/or dermatological field and processes employing it | |
| DE202015009464U1 (en) | cosmetic compositions | |
| US20100029574A1 (en) | Cosmetic compositions | |
| JP3037145B2 (en) | Silicone composition containing water-reactive activator | |
| AU780426B2 (en) | Method for reducing the appearance of dark circles under the eyes | |
| JP2000095663A (en) | Agent for external use containing plant extract | |
| JPH07505383A (en) | Skin care methods and compositions | |
| JPS6251608A (en) | Improved moisture rising lotion | |
| KR20010015900A (en) | Topical Compositions Containing Whey Proteins | |
| JP2001002559A (en) | Turmeric acting as anti-inflammatory agent in composition containing hydroxy acid or retinoid | |
| JP2001122757A (en) | Active oxygen scavenger, antioxidant and cosmetic | |
| JPH06336419A (en) | External agent for skin | |
| JPH11116423A (en) | System for stabilization of ascorbic acid based on phosphoric acid derivative and metabisulfite and composition including the same | |
| JP2003277223A (en) | Matrix metalloprotease inhibitor and skin elasticity- retaining cosmetic | |
| WO2002015864A2 (en) | A vehicle and concentrates for customized personal care products | |
| JPH11116434A (en) | Emulsion containing ascorbic acid and its use | |
| AU2004205161A1 (en) | Stabilized compositions containing an oxygen-labile active agent | |
| CA2051813C (en) | Preparation for care of nails, skin and hair | |
| NZ199153A (en) | Cosmetic moisturiser composition | |
| US5250513A (en) | Antioxidant system based on a basic amino acid in combination with a tocopherol or derivative thereof and a nonthiolated polypeptide, and compositions containing the same | |
| US20040039059A1 (en) | Use of n,n' -dibenzyl ethylene diamine-n, n'- diacetic acid derivatives as anti-pollution agent |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued | ||
| FZDE | Discontinued |
Effective date: 20070501 |